

CV Prof. Dr. Ralph Schermuly

Born: June 12, 1968 in Limburg/Germany
Position: Professor for Pulmonary Pharmacotherapy at Justus-Liebig-University Giessen/Germany
Subject Studied: Biology
Dissertation: 1996, Justus-Liebig-University Giessen
Habilitation: 2005, Justus-Liebig-University, Giessen

Professional Education & International Experience

2003 Research Assistant at the Department of Internal Medicine, Justus-Liebig-University (JLU) Giessen
2005 Habilitation, Pathophysiology and Experimental Pneumology, JLU Giessen
2006 Member Excellence Cluster Cardio Pulmonary System (ECCPS)
2006 Extraordinary Professor for Pathophysiology and Experimental Pneumology at JLU Giessen
2008 Research group leader "Lung Vascular Remodeling and Anti-Remodeling" at the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim, Germany
2008 Steering Board Member and Platform Leader Excellence Cluster Cardio Pulmonary System (ECCPS)
2010 Steering Board Member Universities of Giessen and Marburg Lung Center (UGMLC)
2011 W3-Professor for Pulmonary Pharmacotherapy at JLU Giessen
2012 Member of the German Lung Center (DZL), Area Leader "Pulmonary Hypertension"

Main research areas:

Experimental and Molecular Pneumology, Pulmonary Hypertension, Acute and Chronic Respiratory Insufficiency, Lung Fibrosis, Lung Cancer, Bronchopulmonary Dysplasia, Aerosol Technology

Honors & Awards:

2006 "Pulmonary Arterial Hypertension Award" of the European Respiratory Society
2006 Science Career Award of the Faculty of Medicine of the Justus-Liebig-University Giessen
2007 Co-author of the Galenus-von-Pergamon-Award
2012 "Pulmonary Arterial Hypertension Award" of the European Respiratory Society

Citation Record **Total citations: 20.395** **h-index: 70**
Total number of Pubmed listed publications: 295

Dr. Schermuly is an expert in the field of experimental pathophysiology and pulmonary hypertension. He holds a professorship for Pulmonary Pharmacotherapy at the Justus-Liebig-University since 2011. Co-author of more than 300 peer-reviewed publications, Dr. Schermuly currently is Principal Investigator on a number of grants of the German Research Foundation "Deutsche Forschungsgemeinschaft" (DFG). He is member of the German Lung Center (DZL), the Excellence Cluster Cardio-Pulmonary Institute (CPI) and the Universities of Giessen and Marburg Lung Center (UGMLC). Examples of his "from bench to bedside" research include preclinical investigations of inhaled prostanoids, phosphodiesterase inhibitors, stimulators of soluble guanylate cyclase, receptor tyrosine kinases, or transbronchial surfactant application, providing the basis for worldwide approval of inhaled iloprost, oral sildenafil and riociguat for treatment of pulmonary arterial hypertension.